State of the art in epitope mapping and opportunities in COVID-19
dc.Affiliation | October university for modern sciences and Arts MSA | |
dc.contributor.author | Hamed, Samira M | |
dc.contributor.author | Sakr, Masarra M | |
dc.contributor.author | El-Housseiny, Ghadir S | |
dc.contributor.author | Wasfi, Reham | |
dc.contributor.author | Aboshanab, Khaled M | |
dc.date.accessioned | 2023-03-10T08:58:36Z | |
dc.date.available | 2023-03-10T08:58:36Z | |
dc.date.issued | 2023-03 | |
dc.description.abstract | The understanding of any disease calls for studying specific biological structures called epitopes. One important tool recently drawing attention and proving efficiency in both diagnosis and vaccine development is epitope mapping. Several techniques have been developed with the urge to provide precise epitope mapping for use in designing sensitive diagnostic tools and developing rpitope-based vaccines (EBVs) as well as therapeutics. In this review, we will discuss the state of the art in epitope mapping with a special emphasis on accomplishments and opportunities in combating COVID-19. These comprise SARS-CoV-2 variant analysis versus the currently available immune-based diagnostic tools and vaccines, immunological profile-based patient stratification, and finally, exploring novel epitope targets for potential prophylactic, therapeutic or diagnostic agents for COVID-19. Plain language summary: Epitope mapping is an important tool recently proving efficiency in both diagnosis and vaccine development. Several epitope mapping techniques have been developed for designing sensitive diagnostic tools and developing rpitope-based vaccines (EBVs) as well as therapeutics. In this review, we will discuss the state of the art in epitope mapping, emphasizing accomplishments and opportunities in combating COVID-19. These comprise SARS-CoV-2 variant analysis versus the currently available immune-based diagnostic tools and vaccines and exploring novel epitope targets for potential prophylactic, therapeutic or diagnostic agents for COVID-19. First draft submitted: 29 July 2022; Accepted for publication: 15 February 2023; Published online: 6 March 2023 | en_US |
dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=21100854839&tip=sid&clean=0 | |
dc.identifier.other | 10.2144/fsoa-2022-0048 - C 202 | |
dc.identifier.uri | http://repository.msa.edu.eg/xmlui/handle/123456789/5414 | |
dc.language.iso | en_US | en_US |
dc.publisher | Future Medicine Ltd. | en_US |
dc.relation.ispartofseries | Future Sci. OA;(2023) FSO832 | |
dc.subject | diagnostic tools • | en_US |
dc.subject | epitope-based vaccines • | en_US |
dc.subject | epitope mapping • | en_US |
dc.subject | host-pathogen interface • | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.title | State of the art in epitope mapping and opportunities in COVID-19 | en_US |
dc.type | Article | en_US |